Druggable cancer phosphatases
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Progress has been made in pharmacological targeting of tumor suppressor and oncogenic phosphatases for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Serine/threonine phosphatases: mechanism through structure
Shi, Y. (2009) · Cell · doi:10.1016/j.cell.2009.10.006 · Cited by 1,488
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925
The target landscape of clinical kinase drugs
Klaeger, S., Heinzlmeir, S., Wilhelm, M., Polzer, H., Vick, B., Koenig, P.-A., Reinecke, M., Ruprecht, B., Petzoldt, S., Meng, C., et al. (2017) · Science · doi:10.1126/science.aan4368 · Cited by 854 · cited 1×
“Additional challenges related to kinase inhibitors include lack of specificity among inhibitors targeting structurally very similar active sites across the kinome (10).”
BackgroundCIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677
Self-citationResponse and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., Jin Huh, S., Liang, Y., Ryan, J., et al. (2016) · Nature · doi:10.1038/nature16508 · Cited by 632
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496
Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease
Tartaglia, M., Martinelli, S., Stella, L., Bocchinfuso, G., Flex, E., Cordeddu, V., Zampino, G., van der Burgt, I., Palleschi, A., Petrucci, T. C., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/499925 · Cited by 415 · cited 1×
“SHP2activating mutations such as D61V and E76K, which are frequently associated with leukemias, occur at the interface between the Nterminal SH2 domain and the PTP domain (24, 25).”
BackgroundMutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Ruess, D. A., Heynen, G. J., Ciecielski, K. J., Ai, J., Berninger, A., Kabacaoglu, D., Görgülü, K., Dantes, Z., Wörmann, S. M., Diakopoulos, K. N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0024-8 · Cited by 370
Multiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344 · cited 2×
“Importantly, nongenetic and cancer-selective inhibition of PP2A by inhibitor proteins allows PP2A’s tumor suppressor activity to be therapeutically reactivated (4, 21).”
BackgroundSelf-citationRevealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2
Barford, D., & Neel, B. G. (1998) · Structure · doi:10.1016/s0969-2126(98)00027-6 · Cited by 321
SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models
Fedele, C., Ran, H., Diskin, B., Wei, W., Jen, J., Geer, M. J., Araki, K., Ozerdem, U., Simeone, D. M., Miller, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0444 · Cited by 315 · cited 3×
“Furthermore, combination with SHP099 allowed a decrease in the dose of the MEK inhibitor trametinib, preventing trametinib-associated side effects and resulting in enhanced efficacy in xenograft mouse models of several cancer types (43).”
BackgroundPhase Separation of Disease-Associated SHP2 Mutants Underlies MAPK Hyperactivation
Zhu, G., Xie, J., Kong, W., Xie, J., Li, Y., Du, L., Zheng, Q., Sun, L., Guan, M., Li, H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.002 · Cited by 267
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Wong, G. S., Zhou, J., Liu, J. B., Wu, Z., Xu, X., Li, T., Xu, D., Schumacher, S. E., Puschhof, J., McFarland, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0022-x · Cited by 266 · cited 1×
“Combination of mitogen-activated kinase kinase (MEK) inhibitors with SHP099 was effective against wild-type and KRAS-amplified gastric cancers, both in vitro and in xenograft mouse models (42).”
BackgroundInhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
Bunda, S., Burrell, K., Heir, P., Zeng, L., Alamsahebpour, A., Kano, Y., Raught, B., Zhang, Z.-Y., Zadeh, G., & Ohh, M. (2015) · Nature Communications · doi:10.1038/ncomms9859 · Cited by 249 · cited 1×
“In two studies from the Ohh laboratory, SHP2 was found to directly bind and dephosphorylate K-, N-, and H-RAS in cultured cells (29, 30).”
BackgroundPhenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia
Gutierrez, A., Pan, L., Groen, R. W. J., Baleydier, F., Kentsis, A., Marineau, J., Grebliunaite, R., Kozakewich, E., Reed, C., Pflumio, F., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci65093 · Cited by 220 · cited 1×
“Both of these drug series are derivatives of antipsychotic tricyclic compounds such as phenothiazine (PPZ) (65) that were earlier discovered to have PP2A-activating properties (66).”
BackgroundActivation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
Sangodkar, J., Perl, A., Tohme, R., Kiselar, J., Kastrinsky, D. B., Zaware, N., Izadmehr, S., Mazhar, S., Wiredja, D. D., O’Connor, C. M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89548 · Cited by 196
SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
Zhao, M., Guo, W., Wu, Y., Yang, C., Zhong, L., Deng, G., Zhu, Y., Liu, W., Gu, Y., Lu, Y., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.08.009 · Cited by 190 · cited 1×
“Accordingly, SHP2 inhibition was shown to trigger antitumor immunity and to synergize with PD-1 blockade (38, 39), thus making SHP2 inhibitors potentially promising candidates for cancer immunotherapy.”
BackgroundTherapeutic targeting of oncogenic tyrosine phosphatases
Frankson, R., Yu, Z.-H., Bai, Y., Li, Q., Zhang, R.-Y., & Zhang, Z.-Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1510 · Cited by 189
Selective PP2A enhancement through biased heterotrimer stabilization
Leonard, D., Huang, W., Izadmehr, S., O’Connor, C. M., Wiredja, D. D., Wang, Z., Zaware, N., Chen, Y., Schlatzer, D. M., Kiselar, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.038 · Cited by 176 · cited 15×
“Notably, small-molecule activator of PP2A (SMAP) compounds similar to DT061 were reported originally to both bind to and activate catalytic PP2A-C in the dimeric A-C complex lacking any B subunit (63).”
BackgroundInfluentialDiscovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein
Wang, M., Lu, J., Wang, M., Yang, C.-Y., & Wang, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00471 · Cited by 172 · cited 1×
“(41) developed SHP2-D26 (table S1) that was >30 times more potent than the parent SHP099 compound in the inhibition of ERK phosphorylation and cell growth in two cancer models in vitro (41).”
BackgroundMolecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer
Bollu, L. R., Mazumdar, A., Savage, M. I., & Brown, P. H. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0934 · Cited by 168
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1093 · Cited by 149 · cited 11×
“Although iHAP1 was convincingly shown to mediate its therapeutic effects in ALL via MYBL1 (51), an important future question related to both SMAPs and iHAPs is to determine the direct phosphoprotein targets mediating their therapeutic effects in different cancer types, as their effects on PP2A complexes seem to be cel…”
BackgroundSelf-citationMechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2
Pádua, R. A. P., Sun, Y., Marko, I., Pitsawong, W., Stiller, J. B., Otten, R., & Kern, D. (2018) · Nature Communications · doi:10.1038/s41467-018-06814-w · Cited by 133 · cited 24×
“Furthermore, combination with SHP099 allowed a decrease in the dose of the MEK inhibitor trametinib, preventing trametinib-associated side effects and resulting in enhanced efficacy in xenograft mouse models of several cancer types (43).”
BackgroundInfluentialLaine, A., Sihto, H., Come, C., Rosenfeldt, M. T., Zwolinska, A., Niemelä, M., Khanna, A., Chan, E. K., Kähäri, V.-M., Kellokumpu-Lehtinen, P.-L., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0292 · Cited by 130
Self-citationTyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation
Kano, Y., Gebregiworgis, T., Marshall, C. B., Radulovich, N., Poon, B. P. K., St-Germain, J., Cook, J. D., Valencia-Sama, I., Grant, B. M. M., Herrera, S. G., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08115-8 · Cited by 103
Meeusen, B., & Janssens, V. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.002 · Cited by 96
Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56
Wang, J., Okkeri, J., Pavic, K., Wang, Z., Kauko, O., Halonen, T., Sarek, G., Ojala, P. M., Rao, Z., Xu, W., et al. (2017) · The EMBO Reports · doi:10.15252/embr.201642788 · Cited by 95
Self-citationPP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.009 · Cited by 93
Kauko, O., Imanishi, S. Y., Kulesskiy, E., Yetukuri, L., Laajala, T. D., Sharma, M., Pavic, K., Aakula, A., Rupp, C., Jumppanen, M., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011265 · Cited by 65 · cited 7×
“In general, increased PP2A activity was found to result in drug sensitization (11, 50, 68), establishing pharmacological PP2A reactivation as a possible future strategy to generally combat cancer drug resistance (Fig.”
BackgroundInfluentialSelf-citationCIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice
Ventelä, S., Côme, C., Mäkelä, J.-A., Hobbs, R. M., Mannermaa, L., Kallajoki, M., Chan, E. K., Pandolfi, P. P., Toppari, J., & Westermarck, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033209 · Cited by 58
Self-citationTumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Hao, H.-X., Wang, H., Liu, C., Kovats, S., Velazquez, R., Lu, H., Pant, B., Shirley, M., Meyer, M. J., Pu, M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0170 · Cited by 53
Good Guy in Bad Company: How STRNs Convert PP2A into an Oncoprotein
Kurppa, K. J., & Westermarck, J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.011 · Cited by 12
Self-citation
Research works printed but not linked: 84
- 10.1016/j.biocel.2017.10.017 · DOI · Paper page
- 10.3892/ijmm.2017.3036 · DOI · Paper page
- 10.1093/jnci/djx232 · DOI
- 10.1038/nrc3298 · DOI · Paper page
- 10.1158/1078-0432.CCR-16-0954 · DOI · Paper page
- 10.1111/febs.14617 · DOI · Paper page
- 10.1016/j.celrep.2014.07.036 · DOI · Paper page
- 10.1038/nmeth.1636 · DOI · Paper page
- 10.1038/s41580-018-0015-0 · DOI · Paper page
- 10.1016/j.biocel.2018.01.005 · DOI · Paper page
- 10.1016/j.biocel.2017.09.013 · DOI
- 10.1016/j.semcdb.2016.01.009 · DOI · Paper page
- 10.1016/j.molcel.2009.02.015 · DOI · Paper page
- 10.1016/j.cell.2020.04.005 · DOI · Paper page
- 10.1016/j.cell.2020.12.020 · DOI · Paper page
- 10.1038/ng1156 · DOI · Paper page
- 10.1038/s41467-018-06823-9 · DOI · Paper page
- 10.1021/jm400474r · DOI · Paper page
- 10.1021/jm901645u · DOI · Paper page
- 10.1016/S0092-8674(00)80938-1 · DOI · Paper page
- 10.1093/neuonc/noz107 · DOI
- 10.1126/sciadv.aay4458 · DOI · Paper page
- 10.1158/0008-5472.CAN-19-3038 · DOI · Paper page
- 10.1021/acschembio.7b00980 · DOI · Paper page
- 10.1038/nm.4497 · DOI · Paper page
- 10.15252/embj.2019103695 · DOI · Paper page
- 10.1042/BST20160161 · DOI · Paper page
- 10.1158/0008-5472.CAN-16-1134 · DOI · Paper page
- 10.1016/j.cell.2020.03.051 · DOI · Paper page
- 10.1158/0008-5472.CAN-08-2760 · DOI · Paper page
- 10.1074/jbc.271.19.11059 · DOI · Paper page
- 10.1126/science.1197048 · DOI · Paper page
- 10.7554/eLife.53003 · DOI
- 10.1016/j.ccell.2020.05.019 · DOI · Paper page
- 10.1016/j.ccr.2005.10.015 · DOI · Paper page
- 10.1016/j.bmc.2015.07.007 · DOI · Paper page
- 10.1016/S0021-9258(17)49933-9 · DOI
- 10.1172/JCI126390 · DOI
- 10.1093/braincomms/fcaa002 · DOI
- 10.1172/JCI68951 · DOI · Paper page
- 10.1158/1078-0432.CCR-13-2575 · DOI · Paper page
- 10.3389/fonc.2015.00021 · DOI · Paper page
- 10.1002/emmm.201201283 · DOI · Paper page
- 10.1177/0091270011427908 · DOI
- 10.1096/fj.201802264R · DOI
- 10.1172/JCI31095 · DOI · Paper page
- 10.1038/s41375-018-0288-5 · DOI
- 10.1016/j.canlet.2019.10.007 · DOI
- M. Swingle, L. Ni, R. E. Honkanen, Small-molecule inhibitors of ser/thr protein phosphatases: Specificity, use and common forms of abuse. Methods Mol. Biol. 365, 23–38 (2007).
- 10.1080/15384047.2015.1040961 · DOI · Paper page
- 10.1158/1535-7163.MCT-17-1143 · DOI
- 10.1038/s41467-018-04425-z · DOI · Paper page
- 10.1038/ncb3376 · DOI
- 10.1038/nchembio.1528 · DOI · Paper page
- 10.1074/jbc.C117.819110 · DOI
- 10.1016/j.jmb.2019.06.008 · DOI
- 10.1038/s41467-019-10127-x · DOI
- 10.1074/jbc.M608940200 · DOI · Paper page
- 10.1038/s41375-020-0937-3 · DOI
- 10.1074/jbc.M115.705863 · DOI
- 10.1172/JCI76614 · DOI
- 10.1039/C6OB00946H · DOI
- 10.18632/oncotarget.23787 · DOI
- 10.1124/jpet.119.262188 · DOI
- 10.1172/jci.insight.87607 · DOI
- 10.1002/cam4.772 · DOI · Paper page
- 10.1158/1078-0432.CCR-03-0771 · DOI · Paper page
- 10.1038/onc.2010.449 · DOI
- 10.1158/0008-5472.CAN-06-2644 · DOI
- 10.1073/pnas.95.6.3014 · DOI · Paper page
- 10.1016/j.ccell.2015.05.008 · DOI · Paper page
- 10.1016/j.canlet.2017.10.007 · DOI
- 10.1056/NEJMoa060096 · DOI · Paper page
- 10.1038/nchembio.190 · DOI · Paper page
- 10.1002/cbic.201402000 · DOI
- 10.1038/nm.4310 · DOI · Paper page
- 10.1124/jpet.116.239756 · DOI
- 10.1038/s41586-020-2513-4 · DOI
- 10.1016/j.cell.2006.11.039 · DOI · Paper page
- 10.1126/science.aau0159 · DOI · Paper page
- 10.1073/pnas.2002964117 · DOI
- 10.1158/1055-9965.EPI-05-0121 · DOI · Paper page
- 10.1158/1541-7786.MCR-14-0018 · DOI
- 10.1158/1078-0432.CCR-12-0053 · DOI · Paper page
Cited by
Laine, A., Nagelli, S. G., Farrington, C., Butt, U., Cvrljevic, A. N., Vainonen, J. P., Feringa, F. M., Grönroos, T. J., Gautam, P., Khan, S., et al. (2020) · doi:10.1101/2020.08.27.269902 · Cited by 54
“Importantly, in our model the enhanced TopBP1/RAD51 chromatinrecruitmentisduetolossofadirectandPP2A-independent CIP2A – TopBP1 interaction ( Fig.”
InfluentialSelf-citationHierarchical Hydrogels with Ordered Micro-Nano Structures for Cancer-on-a-Chip Construction
Zhu, L., Shao, C., Chen, H., Chen, Z., & Zhao, Y. (2021) · Research · doi:10.34133/2021/9845679 · Cited by 41
“In clinical practice, numerous therapeutic methods such as surgical resection, drug therapy, chemotherapy and radiotherapy have been adopted [1-3].”
BackgroundVit, G., Duro, J., Rajendraprasad, G., Hertz, E. P. T., Holland, L. K. K., Weisser, M. B., McEwan, B. C., Lopez‐Mendez, B., Sotelo‐Parrilla, P., Jeyaprakash, A. A., et al. (2022) · The EMBO Journal · doi:10.15252/embj.2022110611 · Cited by 34
Cellular toxicity of iHAP1 and DT-061 does not occur through PP2A-B56 targeting
Vit, G., Duro, J., Rajendraprasad, G., Hertz, E. P. T., Kauffeldt Holland, L. K., Weisser, M. B., McEwan, B. C., Lopez-Mendez, B., Montoya, G., Mailand, N., et al. (2021) · doi:10.1101/2021.07.08.451586 · Cited by 33
SHARPIN S146 phosphorylation mediates ARP2/3 interaction, cancer cell invasion and metastasis
Butt, U., Khan, M. H., Pouwels, J., & Westermarck, J. (2022) · Journal of Cell Science · doi:10.1242/jcs.260627 · Cited by 6
Self-citation
Metadata
- Authors
- Vainonen, J. P., Momeny, M., & Westermarck, J.
- Venue
- Science Translational Medicine
- Published
- 2021-04-07
- Volume
- 13
- Issue
- 588
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3140922284
- Cited by
- 104
- References
- 32
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Breast Cancer Now (2017NovPCC1067)
- Foundation of the Finnish Cancer Institute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.